<DOC>
	<DOCNO>NCT02895620</DOCNO>
	<brief_summary>Intravesical BCG immunotherapy use transurethral resection ( TUR ) prevention recurrence NMIBC . BCG treatment usually start week TUR give week 6 week . It stimulate immune response destroy bladder cancer cell ( acute chronic induce inflammation ) consequence cause side effect . The investigator postulate Xpert® test might use demonstrate presence residual ( TURB ) recurrent ( adjuvant treatment ) disease time intravesical treatment , could significant impact management complex situation.Urines BCG treat patient rich immune system element ( cytokine , lymphocyte , … ) , complex inflammatory milieu urine may interfere urinary biomarkers . This study allow assess effect complex inflammatory milieu induce BCG treatment urines patient NMIBC Xpert® Bladder cancer assay .</brief_summary>
	<brief_title>Effect Xpert® Bladder Test Urines Inflammatory Milieu Induced BCG Treatment Patients With NMIBC</brief_title>
	<detailed_description>1 . Qualification Xpert® Testing : Three 50 mL fresh urine sample collect sterile container accord Cepheid instruction use : - `` baseline sample '' first BCG instillation , - `` study sample '' take initiation course treatment instillation , preferably 4th 5th instillation BCG therapy , - `` follow-up sample '' time first follow-up cystoscopy , approximately 3 month last BCG instillation initiation course . Xpert® test result qualify positive negative , accord Cepheid instruction use . Samples test positive baseline include analysis patient 's participation study discontinue . Samples obtain patient recurrence follow-up cystoscopy initiation course consider analysis . 2 . Threshold detection theXpert® Bladder test : - One urine sample patient tumor free ( negative Xpert test ) BCG treatment spike 3 log dilution 2 distinct tumor cell line SW780 BE ( 2 ) -C ( 100 , 1000 , 10000 cell per ml ) . - A mix fresh frozen cell en bloc harvest tumor distinct donor test set concentration BCG urine distinct patient .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Patients present highrisk transitional cell carcinoma bladder , accord EAU guidelines/EORTC risk stratification , offer adjuvant BCG instillation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>